$7.49
0.66%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US2300311063
Symbol
CGEM

Cullinan Oncology Inc Stock price

$7.49
-0.45 5.67% 1M
-0.51 6.38% 6M
-4.69 38.51% YTD
-12.11 61.79% 1Y
-5.71 43.26% 3Y
-13.51 64.33% 5Y
-13.51 64.33% 10Y
-13.51 64.33% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.05 0.66%
ISIN
US2300311063
Symbol
CGEM
Industry

Key metrics

Basic
Market capitalization
$442.5m
Enterprise Value
$177.0m
Net debt
positive
Cash
$265.5m
Shares outstanding
59.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
94.9%
Return on Equity
-28.4%
ROCE
-47.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-234.4m | $-229.5m
EBIT
$-234.7m | $-234.8m
Net Income
$-206.8m | $-222.8m
Free Cash Flow
$-171.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-27.8% | -16.7%
EBIT
-27.7% | -19.2%
Net Income
-45.4% | -33.1%
Free Cash Flow
-35.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.5
FCF per Share
$-2.9
Short interest
11.5%
Employees
111
Rev per Employee
$0.0
Show more

Is Cullinan Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Cullinan Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Cullinan Oncology Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Cullinan Oncology Inc forecast:

Buy
94%
Hold
6%

Financial data from Cullinan Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
18% 18%
-
- Research and Development Expense 178 178
32% 32%
-
-234 -234
28% 28%
-
- Depreciation and Amortization 0.31 0.31
0% 0%
-
EBIT (Operating Income) EBIT -235 -235
28% 28%
-
Net Profit -207 -207
45% 45%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cullinan Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cullinan Oncology Inc Stock News

Neutral
GlobeNewsWire
12 days ago
CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences:
Positive
The Motley Fool
27 days ago
Cullinan (CGEM) Q2 R&D Jumps 68%
Neutral
GlobeNewsWire
27 days ago
CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease
More Cullinan Oncology Inc News

Company Profile

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Nadim Ahmed
Employees 111
Founded 2016
Website cullinantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today